{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.07","value":"0.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Standardized uptake value (SUV) in various organs will be estimated from VOI analysis of clinical images and converted to activity-time curves. The areas under the activity-time curves will be derived by integration, converted to residence times, and used as input to the OLINDA/EXM dosimetry program to obtain absorbed dose estimates for normal tissues for all Phase I participants, regardless of study dose. Each participant underwent four PET/CT scans over the next 8 days, as well as blood chemistry and whole-body counts, to determine safety, tracer biodistribution, pharmacokinetics, and radiation dosimetry. Because 89Zr has a half-life of 78 hours, only a single administration of tracer was needed to obtain all four PET/CT scans for all Phase I participants. Results were combined because all received the same dose of tracer.","dispersionType":"Standard Error","groups":[{"description":"The Phase I portion of the study has concluded. The Phase II portion has not yet opened to accrual.","id":"OG000","title":"89Zr-daratumumab"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"up to 19 months","title":"Average Absorbed Radiation Dose Estimates for Normal Tissues for Phase I Participants","type":"PRIMARY","unitOfMeasure":"mSv/MBq"}